Last reviewed · How we verify
depot medroxyprogesterone acetate
At a glance
| Generic name | depot medroxyprogesterone acetate |
|---|---|
| Also known as | medroxyprogesterone, Depo Provera, DMPA |
| Sponsor | University of Sao Paulo |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease (PHASE4)
- Counseling Among Gender Diverse Adolescents Who Use Depot Medroxyprogesterone (PHASE4)
- Continuation of Subcutaneous and Intramuscular Depot Medroxyprogesterone Acetate in Post-abortion Patients (PHASE4)
- Adolescent Subcutaneous (SQ) Injection Video Validation (NA)
- Comparing the Safety and Efficacy in the Use of Hormonal Therapy on Endometriosis Patients After Conservative Surgery (PHASE3)
- Contraceptive Hormones, Immunity, and Microbiome Evaluation
- Postpartum Family Planning (PHASE4)
- Tranexamic Acid and Depot-Medroxyprogesterone Acetate for Perimenopausal Irregular Uterine Bleeding (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- depot medroxyprogesterone acetate CI brief — competitive landscape report
- depot medroxyprogesterone acetate updates RSS · CI watch RSS
- University of Sao Paulo portfolio CI